OBJECTIVES: To investigate differences between focal and diffuse cervical lesions in multiple sclerosis (MS) by proton magnetic resonance spectroscopy ((1)H-MRS) at 1.5 T in comparison to quantitative MR imaging of the upper cervical cord area and T2 relaxometry at baseline and follow-up. METHODS: Including 22 MS patients with persistent spinal cord symptoms by either diffuse or focal lesions and 17 controls, we acquired MRS, the mean cord area and the water T2 relaxation time and disability at baseline and follow-up. Cross-sectional analyses included group-level comparisons and correlation studies. Follow-up studies covered assessment of reproducibility and progression of the baseline results. RESULTS: Compared with focal lesions, diffuse lesions were attended by more cord atrophy, longer T2, elevated levels of creatine (Cre) and reduced N-acetyl aspartate (NAA)/Cre (focal/diffuse: 83 ± 9/73 ± 15 mm(2), 121 ± 21/104 ± 13 ms, 3.6 ± 1.1/5.1 ± 2.4 mM, 2.4 ± 1.1/2.0 ± 0.9). NAA/Cre at baseline was associated significantly with cord atrophy and with clinical progression during follow-up. Baseline MRS results were not significantly correlated to the clinical disability parameters. The reproducibility of MRS was 0.17-0.30. Longitudinal changes of the MRS results were not statistically significant. CONCLUSIONS: MRS indicated differences in demyelination and gliosis between diffuse and focal cervical lesions in MS. Although longitudinal spectral and clinical changes were sparse, NAA/Cre turned out to be the most sensitive spectral parameter.
OBJECTIVES: To investigate differences between focal and diffuse cervical lesions in multiple sclerosis (MS) by proton magnetic resonance spectroscopy ((1)H-MRS) at 1.5 T in comparison to quantitative MR imaging of the upper cervical cord area and T2 relaxometry at baseline and follow-up. METHODS: Including 22 MSpatients with persistent spinal cord symptoms by either diffuse or focal lesions and 17 controls, we acquired MRS, the mean cord area and the water T2 relaxation time and disability at baseline and follow-up. Cross-sectional analyses included group-level comparisons and correlation studies. Follow-up studies covered assessment of reproducibility and progression of the baseline results. RESULTS: Compared with focal lesions, diffuse lesions were attended by more cord atrophy, longer T2, elevated levels of creatine (Cre) and reduced N-acetyl aspartate (NAA)/Cre (focal/diffuse: 83 ± 9/73 ± 15 mm(2), 121 ± 21/104 ± 13 ms, 3.6 ± 1.1/5.1 ± 2.4 mM, 2.4 ± 1.1/2.0 ± 0.9). NAA/Cre at baseline was associated significantly with cord atrophy and with clinical progression during follow-up. Baseline MRS results were not significantly correlated to the clinical disability parameters. The reproducibility of MRS was 0.17-0.30. Longitudinal changes of the MRS results were not statistically significant. CONCLUSIONS:MRS indicated differences in demyelination and gliosis between diffuse and focal cervical lesions in MS. Although longitudinal spectral and clinical changes were sparse, NAA/Cre turned out to be the most sensitive spectral parameter.
Authors: E Sbardella; V Tomassini; M L Stromillo; N Filippini; M Battaglini; S Ruggieri; L Ausili Cefaro; E Raz; C Gasperini; M P Sormani; P Pantano; C Pozzilli; N De Stefano Journal: Mult Scler Date: 2011-07-05 Impact factor: 6.312
Authors: Charles Gasparovic; Tao Song; Deidre Devier; H Jeremy Bockholt; Arvind Caprihan; Paul G Mullins; Stefan Posse; Rex E Jung; Leslie A Morrison Journal: Magn Reson Med Date: 2006-06 Impact factor: 4.668
Authors: G J Nijeholt; E Bergers; W Kamphorst; J Bot; K Nicolay; J A Castelijns; J H van Waesberghe; R Ravid; C H Polman; F Barkhof Journal: Brain Date: 2001-01 Impact factor: 13.501
Authors: Joseph C J Bot; Erwin L A Blezer; Wouter Kamphorst; Geert J Lycklama A Nijeholt; Herman J Ader; Jonas A Castelijns; Klaas Nicolay Ig; Elisabeth Bergers; Rivka Ravid; Chris Polman; Frederik Barkhof Journal: Radiology Date: 2004-09-22 Impact factor: 11.105
Authors: Fahmy Aboul-Enein; Martin Krssák; Romana Höftberger; Daniela Prayer; Wolfgang Kristoferitsch Journal: PLoS One Date: 2010-07-20 Impact factor: 3.240
Authors: J C J Bot; F Barkhof; C H Polman; G J Lycklama à Nijeholt; V de Groot; E Bergers; H J Ader; J A Castelijns Journal: Neurology Date: 2004-01-27 Impact factor: 9.910
Authors: O Ciccarelli; D R Altmann; M A McLean; C A Wheeler-Kingshott; K Wimpey; D H Miller; A J Thompson Journal: Neurology Date: 2010-01-27 Impact factor: 9.910
Authors: Allan R Martin; Izabela Aleksanderek; Julien Cohen-Adad; Zenovia Tarmohamed; Lindsay Tetreault; Nathaniel Smith; David W Cadotte; Adrian Crawley; Howard Ginsberg; David J Mikulis; Michael G Fehlings Journal: Neuroimage Clin Date: 2015-12-04 Impact factor: 4.881